Third Generics Co. Cut From Eli Lilly ADHD Drug Suit
Eli Lilly & Co. has dropped a third generic-drug company from its patent suit over Strattera, a drug used to treat attention-deficit hyperactivity disorder, after Synthon Laboratories Inc. agreed to withdraw...To view the full article, register now.
Already a subscriber? Click here to view full article